In our study, significant associations were identified between PSMA (p ≤ 0.001) and PCA3 (p ≤ 0.05) expression and clinically significant prostate cancer (Figure 1 and Figure S1a), and among the three genes examined, PSMA emerged as the most reliable single biomarker for predicting clinically significant PCa with an AUC of 0.82 (Figure 2). This evidence concerns the gene PCA3 and posterior cortical atrophy.